Salute e Benessere

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology…

thAnnual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, Oculis’ Chief Financial Officer, will be presenting a corporate update which will be made available for replay via webcast at 7:00am ETSnehal Shah, Oculis’ President of R&D, will be participating in a live panel discussion from 11:00am to 12:00pm ET, on Pivotal-Stage Assets for Retinal Disorders. The panel discussion will also be made available via webcast for replay. Links to access the corporate...
Nasdaq GlobeNewswire
12/08/2025

ViCentra to Bring Smartphone-Based Closed Loop Therapy to People with Diabetes…

The new system combines ViCentra's discreet and featherlight Kaleido patch pump with Diabeloop's DBLG2 app-based algorithm—enabling automated insulin delivery controlled directly from the user's smartphone. The integration of Dexcom G7, which is 60% smaller than its predecessor and features an all-in-one sensor and transmitter, significantly enhances comfort and ease of use. The new system combines ViCentra's discreet and featherlight Kaleido patch pump with Diabeloop's DBLG2 app-based...
PR Newswire
12/08/2025

ClariMed Inc. Acquires We Are Human, Expanding Growth into Southeast Market

Annmarie Nicolson, founder of We Are Human, will join ClariMed as Principal, bringing her extensive experience in early-stage formative research, contextual inquiry, and UX research for MedTech innovation to the leadership team. The acquisition brings the complete We Are Human team and their Atlanta research facility into the ClariMed family, expanding the company's presence in the Southeast region. Annmarie Nicolson, founder of We Are Human, will join ClariMed as Principal, bringing her...
PR Newswire
12/08/2025

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating…

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated with ianalumab also experienced a significantly higher rate of sustained improvements in platelet count, the key secondary endpoint of the study 1 Ianalumab, administered as four once-monthly doses in the ITP setting, could offer long-term disease control through a short course...
Nasdaq GlobeNewswire
12/08/2025

Sandoz launches renewable energy partnership to cover nearly 90% of electricity…

MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in SpainWill cover nearly 90% of electricity demand for European operationsConcrete step to support global Sandoz decarbonization efforts and sustainability commitmentBasel, August 12, 2025 –Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the signing of a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy, a global...
Nasdaq GlobeNewswire
12/08/2025

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmedSaint-Herblain (France), August 12, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year, ended June 30, 2025, and confirmed its 2025...
Nasdaq GlobeNewswire
12/08/2025

Tecan reports solid financial results for the first half of 2025 and confirms…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports solid financial results for the first half of 2025and confirms its outlook for full year 2025Financial results for the first half of 2025 – Highlights Sales of CHF 439.5 million (H1 2024: CHF 467.2 million) Sales development of -3.7% in local currencies or -5.9% in Swiss francs,in line with expectationsLife Sciences Business segment returning to growth; Partnering...
Nasdaq GlobeNewswire
12/08/2025

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period…

Key Takeaways from the IBAT Inhibitors Market Report Key Takeaways from the IBAT Inhibitors Market Report Discover which indication is expected to grab the major IBAT inhibitors market share @IBAT Inhibitors Market Report IBAT Inhibitors Market Dynamics The market dynamics for IBAT inhibitors are shaped by a confluence of factors, includingrising prevalence of rare cholestatic liver diseases, growing awareness of pediatric liver disorders, and theincreasing regulatory...
PR Newswire
11/08/2025

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual…

Daix (France), New York City (New York, United States), August 11, 2025 –Inventiva(Euronext Paris and NASDAQ:IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a...
Nasdaq GlobeNewswire
11/08/2025

Global Telemedicine Market to Grow at 11.3% CAGR Through 2030

This report offers a comprehensive review of the telemedicine technologies market, focusing on its rapid growth. key players and their competitive strategies, innovations, and regional opportunities, while also examining market drivers like virtual consultations and patient demand for remote care. The market is segmented by hardware, software, and services, and categorized by end-users such as homes and healthcare providers. It also explores emerging technologies, regulatory landscapes, and…
PR Newswire
11/08/2025

NTG Nordic Transport Group publishes interim report for H1 2025

Company announcement no. 9 – 25 11 August 2025 NTG Nordic Transport Group publishes interim report for H1 2025The interim report for H1 2025 is enclosed.In connection with publication of the results for H1 2025, a conference call will be hosted on 12 August 2025 at 10:00 AM CEST.The conference call will be held in English and can be followed live via NTG’s website ; investor.ntg.com. Additional information For additional information, please contact: Investor relations and...
Nasdaq GlobeNewswire
11/08/2025

Wound Care Market worth US$30.48 billion by 2030 with 6.5% CAGR |…

Browse in-depth TOC on "Wound Care Market" Browse in-depth TOC on "Wound Care Market" 589 - Tables 61 - Figures 457 - Pages By wound type,the wound care market is divided into two main segments based on wound type: chronic wounds and acute wounds. Chronic wounds are further divided into diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other chronic wounds. The chronic wounds segment of the wound care held the largest market share in 2024. Chronic wounds...
PR Newswire
11/08/2025

Flow Cytometry Market worth US$9.85 billion in 2033 with 8.7% CAGR |…

Browse in-depth TOC on "Flow Cytometry Market"722 - Tables59 - Figures511 - Pages Browse in-depth TOC on "Flow Cytometry Market" 722 - Tables 59 - Figures 511 - Pages By offering,the flow cytometry market is segmented into software, services, reagents & consumables (antibodies, assays & kits, and other reagents & consumables), instruments, and accessories. Reagents & consumables accounted for the largest share of the flow cytometry market in 2024. The large...
PR Newswire
11/08/2025

Compounding Pharmacy Market and Pharma Manufacturing Poised for Strong, Parallel…

The compounding pharmacy market, valued at approximately USD 15.1 billion in 2025, is forecast to reach nearly USD 20 billion by 2030, registering a compound annual growth rate (CAGR) of 5.7%, says Mordor Intelligence. Growth stems from rising demand for customized medications, chronic pain management alternatives, and expanded bio-identical hormone therapies. Personalized formulations for pediatric and geriatric patients further bolster market uptake, ensuring precise dosing and improved…
PR Newswire
11/08/2025

Intas & Accord signs Agreement to acquire Prothya Biosolutions

Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe's largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of…
PR Newswire
11/08/2025

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need as there are currently no FDA...
Nasdaq GlobeNewswire
11/08/2025

Evaxion to announce business update and second quarter 2025 financial results on…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM.Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged...
Nasdaq GlobeNewswire
11/08/2025

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and…

- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October -- VCN-01 demonstrates potential in retinoblastoma with Phase 1 safety and clinical outcome data presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting -- Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026 -...
Nasdaq GlobeNewswire
11/08/2025

Turtlebrace is now available through SPS and at Hanger Clinics Across the U.S.

"This new agreement marks a significant milestone in helping to expand access to our remoldable, waterproof, and lightweight braces products to patients who need it," said Turtlebrace developer Serge-Eric Blais. "It is a giant step towards meeting our company's mission to help as many people as possible with solutions to get them back to their normal lives." "This new agreement marks a significant milestone in helping to expand access to our remoldable, waterproof, and…
PR Newswire
11/08/2025

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR…

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –– Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with no currently approved medicines that address the underlying cause of the disease – CAMBRIDGE, Mass. and BEDFORD, Mass., Aug.11, 2025(GLOBE NEWSWIRE) --Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a...
Nasdaq GlobeNewswire
11/08/2025

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug…

Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumorsMilestone in drive to redefine cancer treatment with precision oncology therapyBasel, Switzerland – August 11, 2025– FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced...
Nasdaq GlobeNewswire
11/08/2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and…

Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company’s Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of...
Nasdaq GlobeNewswire
11/08/2025

Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global…

This partnership leverages IQVIA's deep expertise in global clinical trial design, regulatory strategy, and data-driven insights. By combining Kexing's innovative product pipeline with IQVIA's global operational infrastructure, the two companies aim to enhance trial efficiency, and enable faster access to international markets. The collaboration is expected to significantly strengthen Kexing's global development capabilities and accelerate its transition toward becoming an international…
PR Newswire
11/08/2025

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for…

WuXi Biologics developed WuXia293Stable by leveraging its proprietary HEK293 cell line. Derived from WuXi Biologics' highly-vetted mammalian cell line development platform family WuXia™, WuXia293Stable demonstrates productivity, quality and stability comparable to WuXia™ while maintaining full compatibility with its process, as shown by its robust growth and balanced metabolism. WuXi Biologics developed WuXia293 Stableby leveraging its proprietary HEK293 cell line. Derived from WuXi...
PR Newswire
11/08/2025
Altri  Comunicati